Core Viewpoint - The company has received approval from the National Medical Products Administration (NMPA) in China for its core product, the BroncAblate intelligent radiofrequency ablation system, marking a significant step in the commercialization of the world's first bronchoscopic radiofrequency ablation device for lung cancer treatment [1][2]. Group 1 - The BroncAblate intelligent ablation system consists of the BroncAblate intelligent catheter and the main unit, which is the first device confirmed through large-scale, high-quality clinical studies for bronchoscopic lung cancer radiofrequency ablation [1]. - The system allows real-time monitoring of the ablation area, including temperature and impedance, providing a visual representation of the treatment process and enabling intelligent adjustment of output power for stable and controllable radiofrequency energy delivery [1]. - The device aims to achieve better ablation efficacy with minimal damage and fewer complications for patients, enhancing the overall treatment experience [1]. Group 2 - The BroncAblate intelligent catheter, when connected to the main unit, utilizes saline infusion to effectively reduce impedance and deliver radiofrequency energy precisely to the tumor center in the lungs, resulting in a minimally invasive intervention for lung tumors [2]. - This innovative approach fills a global gap in the field of targeted micro-invasive therapies for lung cancer, offering significant benefits over traditional methods [2].